PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A case report and review of the literature.

Abstract Melanoma with brain metastasis is associated with a poor prognosis and high mortality rate. As patients with this condition have been excluded from most clinical trials, data on the use of anti-programmed death 1 therapy for these patients are limited.
PMID
Related Publications

Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

The use of pembrolizumab for the treatment of metastatic uveal melanoma.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29390382
OWN - NLM
STAT- MEDLINE
DCOM- 20180212
LR  - 20180212
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 50
DP  - 2017 Dec
TI  - Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A
      case report and review of the literature.
PG  - e9278
LID - 10.1097/MD.0000000000009278 [doi]
AB  - RATIONALE: Melanoma with brain metastasis is associated with a poor prognosis and
      high mortality rate. As patients with this condition have been excluded from most
      clinical trials, data on the use of anti-programmed death 1 therapy for these
      patients are limited. PATIENT CONCERNS: The patient was a 62-year-old man with a 
      10-year history of melanotic nevus in his right forearm. He was admitted to
      another hospital in August 2015 due to the growth of the melanotic nevus over 1
      year and complaint of a mass in the right mid-axillary area. The patient had no
      relevant medical, surgical, or family history. DIAGNOSES: The biopsy of his right
      axillary lymph node showed malignant melanoma. INTERVENTIONS: He was subsequently
      treated with adjuvant high-dose interferon after dacarbazine. Numerous metastatic
      lesions were found in his lung, abdomen, pelvic cavity, and brain after five
      months later, and then Pembrolizumab was used for six cycles (2 mg/kg every 3
      weeks). He experienced immunorelated adverse events and we gave him cortisol to
      treat immunorelated disease until pneumonia was found. OUTCOMES: We observed a
      delayed effect after three cycles of Pembrolizumab, the intracranial lesion
      presented clear margins and localization, while the other lesions became much
      smaller. A mixed response was observed after four cycles, with still stable
      extracranial metastases but growing a new lesion in brain. After two additional
      cycles of Pembrolizumab, the treatment was stopped due to the patient's inability
      to pay for it and a decline in his performance status. He then received
      palliative treatment at a local hospital and died for severe pulmonary infection,
      with an overall survival time of 7 months from metastasis. LESSONS: In the case
      reported here, a delayed and mixed response was observed after Pembrolizumab was 
      used. Because of causing severe pulmonary infection, the use of steroids should
      be considered carefully when treating immunorelated adverse events. It seemed
      that the Pembrolizumab has a positive effect on melanoma brain metastases
      especially combined with other treatments. However, there are still some
      challenges including patient selection, predictors of response, drug tolerance,
      optimizing combination strategies and control of adverse effects. More carefully 
      designed clinical trials are urgently needed.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Song, Jin-Cheng
AU  - Song JC
AD  - Department of Oncology, the Second Affiliated Hospital of Dalian Medical
      University, Dalian, China.
FAU - Ding, Xiao-Lei
AU  - Ding XL
FAU - Sun, Xiu-Hua
AU  - Sun XH
FAU - Safi, Mohammed
AU  - Safi M
FAU - Tian, Juan
AU  - Tian J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - DPT0O3T46P (pembrolizumab)
RN  - Melanoma, Cutaneous Malignant
SB  - AIM
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Biopsy
MH  - Brain Neoplasms/*secondary
MH  - Fatal Outcome
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Male
MH  - Melanoma/*drug therapy/*pathology
MH  - Middle Aged
MH  - Skin Neoplasms/*drug therapy/*pathology
EDAT- 2018/02/03 06:00
MHDA- 2018/02/13 06:00
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/13 06:00 [medline]
AID - 10.1097/MD.0000000000009278 [doi]
AID - 00005792-201712150-00132 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(50):e9278. doi: 10.1097/MD.0000000000009278.